Computational study of the effect of polysaccharide encapsulation on anti-cancer property of imatinib (Record no. 4944)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01937nam a22001817a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220107122808.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 160302b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Priya.R (92213011) |
| 9 (RLIN) | 8339 |
| 245 ## - TITLE STATEMENT | |
| Title | Computational study of the effect of polysaccharide encapsulation on anti-cancer property of imatinib |
| 502 ## - DISSERTATION NOTE | |
| Degree type | Master of Science in Computational Science |
| Name of granting institution | 2013-2015 |
| Year degree granted | EXT |
| -- | T.K Manoj Kumar |
| -- | T.T Sreelekha ( Assistant Professor ) |
| Miscellaneous information | "Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC)" |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Imatinib is an antineoplastic agent used against Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GISTs) and various other malignancies. Its action is different than other drugs in that it specifically targets an enzyme that allows CML cells to grow. Drug resistance associated with imatinib is the main problem facing in the treatment of patients. Nanoscale drug encapsulation becomes an outstanding approach to the medical field, thereby, avoids the side effects that occur in the traditional cancer treatment. Structure based drug design offers a computational approach to find out a lead compound that could become a drug. The present computational study aimed at the modification of a drug which is used for treating cancer patients for better results. A model of Galactoxyloglucan encapsulated Imatinib has been developed and computed the activity of this encapsulated drug against various cancer causing pathways such as DNA topoisomerase 2-beta(3QX3), Epidermal growth factor receptor(1M17) and Tyrosine-protein kinase ABL1(3QRJ). Computations indicate that the polysaccharide encapsulated drug is highly effective and targeted towards different cancer causing pathways. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | APPLIED COMPUTING |
| 9 (RLIN) | 8340 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | PHYSICAL SCIENCES AND ENGINEERING |
| 9 (RLIN) | 8341 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | CHEMISTRY |
| 9 (RLIN) | 8342 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | IIITM-K | Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre | 02/03/2016 | R-658 | 02/03/2016 | 02/03/2016 | Project Reports |